DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://www.oncotarget.com/article/10195/text/, but it redirected us to https://www.oncotarget.com/article/10195/text/. The analysis below is for the second page.

Title[redir]:
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers | Oncotarget
Description:
// Rana Hatem 1, 2 , Rania El Botty 3 , Sophie Chateau-Joubert 4 , Jean-Luc Servely 4, 5 , Dalila Labiod 3 , Ludmilla de Plater 3 , Franck Assayag 3 , Florence Coussy 1, 3, 8 , Céline Callens 1 , Sophie Vacher 1 , Fabien Reyal 3, 6 , Sabina Cosulich 7 , Véronique Diéras 8 , Ivan Bièche 1, 9, * , Elisabetta Marangoni 3, * 1 Genetics Department, Institut Curie, PSL Research University, Paris, France 2 Faculty of Pharmacy, Aleppo University, Aleppo, Syria 3 Translational Research Department, Institut Curie, PSL Research University, Paris, France 4 BioPôle Alfort, National Veterinary School of Alfort, Maisons Alfort, France 5 INRA, PHASE Department, Paris, France 6 Surgery Department, Institut Curie, PSL Research University, Paris, France 7 AstraZeneca R&D Cambridge, CRUK Cambridge Institute, Cambridge, UK 8 Medical Oncology Department, Institut Curie, PSL Research University, Paris, France 9 EA7331, University of Paris Descartes, Paris, France * These authors have contributed equally to this work Correspondence to: Elisabetta Marangoni, email: [email protected] Keywords: TNBC, mTOR, PI3K pathway, PDX Received: January 25, 2016&emsp;&emsp;&emsp;&emsp; Accepted: June 09, 2016&emsp;&emsp;&emsp;&emsp; Published: June 21, 2016 ABSTRACT Triple-negative breast cancers (TNBC) are characterized by frequent alterations in the PI3K/AKT/mTOR signaling pathway. In this study, we analyzed PI3K pathway activation in 67 patient-derived xenografts (PDX) of breast cancer and investigated the anti-tumor activity of the mTOR inhibitor everolimus in 15 TNBC PDX with different expression and mutational status of PI3K pathway markers. Expression of the tumor suppressors PTEN and INPP4B was lost in 55% and 76% of TNBC PDX, respectively, while mutations in PIK3CA and AKT1 genes were rare. In 7 PDX treatment with everolimus resulted in a tumor growth inhibition higher than 50%, while 8 models were classified as low responder or resistant. Basal-like, LAR (Luminal AR), mesenchymal and HER2-enriched tumors were present in both responder and resistant groups, suggesting that tumor response to everolimus is not restricted to a specific TNBC subtype. Analysis of treated tumors showed a correlation between tumor response and post-treatment phosphorylation of AKT, increased in responder PDX, while PI3K pathway markers at baseline were not sufficient to predict everolimus response. In conclusion, targeting mTOR decreased tumor growth in 7 out of 15 TNBC PDX tested. Response to everolimus occurred in different TNBC subtypes and was associated with post-treatment increase of P-AKT.

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 91,115,781 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pdx, hbcx, cancer, everolimus, models, breast, tumors, tumor, expression, akt, inhibition, mtor, tnbc, pten, response, responder, pathway, inppb, loss, figure, treatment, analysis, resistant, pik, signaling, lost, pakt, cell, triplenegative, activation, mtorc, krt, growth, xenografts, activity, azd, treated, phosphorylation, pikca, inhibitors, results, analyzed, western, res, inhibitor, human, vivo, blot, idc, mutations,

Topics {✒️}

acid-phenol guanidium method tata box-binding protein inter-scapular fat pad mitogen-activated protein kinase specific pathogen-free conditions triple-negative breast cancers pi3k/akt/mtor signaling pathway triple-negative breast cancer estrogen receptor-responsive gene post-treatment p-akt reactivation relative tumor volume pi3k/akt/mtor pathway inhibitors female nude mice improved anti-tumor activity perkin-elmer applied biosystems inaugural editorial pi3k-dependent feedback loop 67 patient-derived xenografts patient-derived xenografts p-akt/akt ratio quantified increased anti-tumor activity tailed student t-test treated/untreated p-akt/akt high p-akt/akt ratio receptor tyrosine kinases publication alerts subscribe pi3k/akt feedback loop free publication horseradish peroxydase complex supplementary figure s3-s5 feedback-dependent biphasic regulation open-access journal dedicated raf/mek/erk pathways confirm rt-pcr results pi3k–akt-mtor signaling post-treatment increased phosphorylation hormone receptor positive anti rabbit omnimap pi3k–akt-mtor pathway pi3k/akt/mtor pathway pi3k/akt/ mtor pathway rt-pcr expression analysis advanced breast cancer p-akt/akt quantified quantify p-s6/s6 high p-akt levels pi3k/akt/mtor activation tumors include loss/mutation 3 triple-negative tumors p-s6 expression differences

Schema {🗺️}

Article:
      license:https://creativecommons.org/licenses/by/4.0/
      publisher:
         type:Organization
         name:Oncotarget
         logo:
            type:ImageObject
            url:https://www.oncotarget.com/images/oncotarget-logo-square.png
            width:1200
            height:1200
      dateModified:2016-12-26T01:01:26Z
      mainEntityOfPage:
         type:WebPage
         id:https://www.oncotarget.com/article/10195/text/
      headline:Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast canc
      articleSection:Research Papers
      sameAs:https://doi.org/10.18632/oncotarget.10195
      image:https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=viewFile&path%5B%5D=10195&path%5B%5D=32084&path%5B%5D=160431
      datePublished:2016-06-21T00:00:00Z
      author:
            type:Person
            name:Hatem, Rana
            type:Person
            name:Botty, Rania El
            type:Person
            name:Chateau-Joubert, Sophie
            type:Person
            name:Servely, Jean-Luc
            type:Person
            name:Labiod, Dalila
            type:Person
            name:Plater, Ludmilla de
            type:Person
            name:Assayag, Franck
            type:Person
            name:Coussy, Florence
            type:Person
            name:Callens, Céline
            type:Person
            name:Vacher, Sophie
            type:Person
            name:Reyal, Fabien
            type:Person
            name:Cosulich, Sabina
            type:Person
            name:Diéras, Véronique
            type:Person
            name:Bièche, Ivan
            type:Person
            name:Marangoni, Elisabetta
Organization:
      name:Oncotarget
      logo:
         type:ImageObject
         url:https://www.oncotarget.com/images/oncotarget-logo-square.png
         width:1200
         height:1200
ImageObject:
      url:https://www.oncotarget.com/images/oncotarget-logo-square.png
      width:1200
      height:1200
WebPage:
      id:https://www.oncotarget.com/article/10195/text/
Person:
      name:Hatem, Rana
      name:Botty, Rania El
      name:Chateau-Joubert, Sophie
      name:Servely, Jean-Luc
      name:Labiod, Dalila
      name:Plater, Ludmilla de
      name:Assayag, Franck
      name:Coussy, Florence
      name:Callens, Céline
      name:Vacher, Sophie
      name:Reyal, Fabien
      name:Cosulich, Sabina
      name:Diéras, Véronique
      name:Bièche, Ivan
      name:Marangoni, Elisabetta

Social Networks {👍}(6)

External Links {🔗}(80)

Analytics and Tracking {📊}

Google Analytics
Google Analytics 4
Google Tag Manager
Google Universal Analytics

Libraries {📚}

Foundation
jQuery

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Cloudflare

4.34s.